ACTO Unveils the Next-Generation LAICA™: A Revolutionary AI Knowledge Assistant for Pharma Field Teams
In an exciting development for the pharmaceutical industry, ACTO, a long-standing technology partner of Veeva, has introduced the latest iteration of its Life Sciences AI Conversational Assistant, LAICA™. This innovative tool is set to revolutionize how field teams interact with healthcare professionals (HCPs) by providing them with instantaneous access to critical knowledge and insights tailored to their specific needs.
At the core of LAICA™ is its enhanced emotional intelligence and an expanded knowledge base that equips field representatives with the ability to engage in meaningful conversations. Imagine a scenario where a pharmaceutical sales rep approaches a provider who has over 15 years of expertise compared to their own. In such moments, LAICA™ will step in to provide rapid answers to last-minute queries, ensuring the rep feels poised and prepared as they transition from the parking lot to the clinic. This type of immediate support is invaluable, allowing for maximized impact during crucial interactions with HCPs.
As stated by ACTO’s CEO, Parth Khanna, the evolution of AI is ongoing and adaptive, continuously learning to deliver precise, relevant, and personalized responses. With this next generation of LAICA™, the tool not only interprets user inquiries but also understands the context and emotional undertones behind questions, making it an exceptionally intuitive assistant. LAICA™ aims to meet professionals where they are, helping them navigate their roles more confidently.
LAICA™ will also integrate multiple connectors to authorized content sources, allowing for the swift and accurate delivery of relevant promotional and scientific data. Content provided will include training materials, up-to-date journal articles, and real-time client data. This comprehensive “knowledge universe” significantly enhances LAICA™’s cognitive capabilities, enabling it to handle intricate data and generate reliable, compliant responses.
Additionally, LAICA™ is designed to evolve its emotional intelligence by taking into account the individual experiences, skills, and confidence levels of each user. This enhances the personalization of its interactions, as it will offer proactive suggestions, deepening the user’s understanding of key subjects and better preparing them for meetings with healthcare providers.
"Our ultimate goal is to enable our field teams to have personalized and productive conversations with healthcare professionals," commented Lisa Dreher, National Sales Training Director at Currax Pharmaceuticals. "LAICA™ will achieve this by granting field professionals quick and specific access to the necessary knowledge, along with relevant suggestions home in on planning before calls and enhancing the quality of every interaction with HCPs."
The unveiling of LAICA™ will take place at the Veeva Commercial Summit in Boston on May 13-14, 2025. Attendees will have a first-hand opportunity to see this cutting-edge tool in action. For more updates and the latest news from ACTO, visit their website at www.acto.com or follow them on LinkedIn.
Founded with the mission of transforming field professionals into skilled communicators, ACTO offers a smart field excellence platform that combines AI with proven strategies for life sciences. As an FDA 21 CFR Part 11-compliant and SOC 2 Type II certified platform, ACTO remains a trusted partner in enhancing operational efficiency for sales, marketing, and medical teams in the life sciences sector. © 2025 ACTO Technologies, Inc. All trademarks and brands are the property of their respective owners.
For media inquiries, please contact Robert Minicucci at ACTO at [email protected] or +1 339 206 1722.
At the core of LAICA™ is its enhanced emotional intelligence and an expanded knowledge base that equips field representatives with the ability to engage in meaningful conversations. Imagine a scenario where a pharmaceutical sales rep approaches a provider who has over 15 years of expertise compared to their own. In such moments, LAICA™ will step in to provide rapid answers to last-minute queries, ensuring the rep feels poised and prepared as they transition from the parking lot to the clinic. This type of immediate support is invaluable, allowing for maximized impact during crucial interactions with HCPs.
As stated by ACTO’s CEO, Parth Khanna, the evolution of AI is ongoing and adaptive, continuously learning to deliver precise, relevant, and personalized responses. With this next generation of LAICA™, the tool not only interprets user inquiries but also understands the context and emotional undertones behind questions, making it an exceptionally intuitive assistant. LAICA™ aims to meet professionals where they are, helping them navigate their roles more confidently.
LAICA™ will also integrate multiple connectors to authorized content sources, allowing for the swift and accurate delivery of relevant promotional and scientific data. Content provided will include training materials, up-to-date journal articles, and real-time client data. This comprehensive “knowledge universe” significantly enhances LAICA™’s cognitive capabilities, enabling it to handle intricate data and generate reliable, compliant responses.
Additionally, LAICA™ is designed to evolve its emotional intelligence by taking into account the individual experiences, skills, and confidence levels of each user. This enhances the personalization of its interactions, as it will offer proactive suggestions, deepening the user’s understanding of key subjects and better preparing them for meetings with healthcare providers.
"Our ultimate goal is to enable our field teams to have personalized and productive conversations with healthcare professionals," commented Lisa Dreher, National Sales Training Director at Currax Pharmaceuticals. "LAICA™ will achieve this by granting field professionals quick and specific access to the necessary knowledge, along with relevant suggestions home in on planning before calls and enhancing the quality of every interaction with HCPs."
The unveiling of LAICA™ will take place at the Veeva Commercial Summit in Boston on May 13-14, 2025. Attendees will have a first-hand opportunity to see this cutting-edge tool in action. For more updates and the latest news from ACTO, visit their website at www.acto.com or follow them on LinkedIn.
Founded with the mission of transforming field professionals into skilled communicators, ACTO offers a smart field excellence platform that combines AI with proven strategies for life sciences. As an FDA 21 CFR Part 11-compliant and SOC 2 Type II certified platform, ACTO remains a trusted partner in enhancing operational efficiency for sales, marketing, and medical teams in the life sciences sector. © 2025 ACTO Technologies, Inc. All trademarks and brands are the property of their respective owners.
For media inquiries, please contact Robert Minicucci at ACTO at [email protected] or +1 339 206 1722.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.